Clinical trials: Ticagrelor
Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
Prasugrel Or Ticagrelor De-escalation in NSTE-ACS
The PROTEUS study is a randomized, cross-over, open-label, pharmacodynamic trial designed to compare the antiplatelet effect of reduced maintenance doses of prasugrel and ticagrelor in stable patients who recently had…
- Conditions
- Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina
- Trial name
- PROTEUS (NCT05779059)
- Testing
- De-escalation to ticagrelor 60 mg at day 30, De-escalation to prasugrel 5 mg at day 30, Switch to ticagrelor 60 mg at day 45
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Non ST Segment Elevation Acute Coronary Syndrome
Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy
Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces the risk of stent thrombosis, myocardial infarction and stroke after coronary stent implantation.
- Trial name
- OPTICA (NCT04766437)
- Testing
- Prasugrel 10mg, Ticagrelor 90mg
- Where
- Netherlands
- Volunteers
- 75 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Acute Coronary Syndrome (ACS)
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned invasive strategy in terms of clinical outcomes.
- Trial name
- ISAR-REACT 5 (NCT01944800)
- Testing
- Ticagrelor, Prasugrel
- Where
- 19 sites in Germany, Italy
- Volunteers
- 4,018 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Acute Coronary Syndrome
ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome
Ticagrelor 90 mg twice daily treatment is recommended for 12 months in patients with acute coronary syndrome (ACS) and in patients undergoing coronary revascularization and conservative strategies.
- Trial name
- AD-HOC (NCT03129867)
- Testing
- Ticagrelor
- Volunteers
- 480 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Stable Angina, Unstable Angina
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems…
- Conditions
- Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction
- Trial name
- HOST-IDEA (NCT02601157)
- Testing
- 3-months DAPT, 1-year DAPT
- Where
- 12 sites in South Korea
- Volunteers
- 2,173 people
- Sponsor
- Seoul National University Hospital
Chronic Kidney Diseases, Heart Attack
Chronic Kidney Disease (CKD) Platelet Study
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys.
- Conditions
- Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
- Trial name
- NCT03649711
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Coronary Artery Disease
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study
Besides being at least as effective as prasugrel in inhibiting platelet aggregation, ticagrelor has been shown to have additional properties potentially affecting coronary microcirculation.
- Trial name
- PROMICRO-3 (NCT05643586)
- Testing
- Ticagrelor, Prasugrel
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Germano Di Sciascio
Saphenous Vein Graft Disease
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous vein graft disease remains an unresolved medical problem. Many vein grafts occlude in the first year after bypass surgery, leading to adverse cardiovascular outcomes, including recurrent angina, myocardial infarction…
- Trial name
- TARGET (NCT02053909)
- Testing
- Aspirin, Ticagrelor
- Where
- 2 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Boca Raton Regional Hospital
Healthy Individuals
Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition
Single oral administration of study drugs (i.e. Anplag® \& Brilinta®) in Two periods after at least 10 hours fasting. The periods will be separated by a washout period of 7 days.
- Trial name
- BE (NCT04941196)
- Testing
- Anplag (Ticagrelor 90 mg), Brilinta (Ticagrelor 90 mg)
- Where
- Pakistan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Karachi
Coronary Artery Disease (CAD)
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile
Several studies have shown that pharmacodynamic (PD) response varies between patients treated with clopidogrel and that individuals with reduced response have an increased risk of recurrent ischemic events, particularly in…
- Trial name
- NCT05516784
- Testing
- Clopidogrel, Ticagrelor
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- Universiti Sains Malaysia
Cardiovascular Diseases, Acute Coronary Syndrome
Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence
This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers.
- Trial name
- NCT05474053
- Testing
- Ticagrelor 90mg (Brilique), Ticagrelor 90mg (Ticaloguard)
- Where
- Egypt
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cairo University
Coronary Artery Disease
SAPT Versus DAPT in Incomplete Revascularization After CABG
The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary artery bypass graft surgery (CABG).
- Trial name
- SDAT-IRC (NCT03789916)
- Testing
- Ticagrelor, acetylsalicylic acid
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Campus Bio-Medico University
Aortic Stenosis, Inflammation
Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)
The central hypothesis of this study is that TAVR leads to platelet deposition and inflammatory cell activation that can be attenuated by the potent anti-platelet and/or pleiotropic effects of ticagrelor.
- Conditions
- Aortic Stenosis, Inflammation, Thrombosis
- Trial name
- NCT02486367
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University Hospitals Cleveland Medical Center
Acute Coronary Syndrome, STEMI
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
Elderly individuals are increasingly represented among patients with acute coronary syndrome (ACS). Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 receptor inhibitor has an established role in the prevention of…
- Conditions
- Acute Coronary Syndrome, STEMI, NSTEMI, Coronary Artery Disease
- Trial name
- PlinytheElder (NCT04739384)
- Testing
- Ticagrelor 90mg, Ticagrelor 60 mg
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Federico II University
Thrombosis
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of gender.
- Trial name
- NCT04945616
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Carotid Artery Stenosis
Ticagrelor Versus Clopidogrel in Carotid Artery Stenting
Patients with symptomatic or asymptomatic carotid stenosis in whom carotid artery stenting is planned are randomised between antiplatelet therapy with ticagrelor plus aspirin or clopidogrel plus aspirin and examined with brain…
- Trial name
- PRECISE-MRI (NCT02677545)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 210 people
- Sponsor
- University Hospital, Basel, Switzerland
ST-segment Elevation Myocardial Infarction
EROSION II: OCT Guided PPCI in STEMI
This protocol describes a prospective, multi-center study intended to test the hypothesis that patients with STEMI caused by plaque rupture or plaque erosion without obstructive stenosis (diameter stenosis <70%) can be stabilized…
- Trial name
- NCT03062826
- Testing
- dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)
- Where
- 16 sites in China
- Volunteers
- 347 people
- Sponsor
- Harbin Medical University
Acute Coronary Syndrome, Bleeding
The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome
A retrospective real world analysis of bleeding events with ticagrelor compared to clopidogrel in ACS patients.
- Conditions
- Acute Coronary Syndrome, Bleeding, Novel Anti-platelets, Ticagrelor
- Trial name
- ROBOT-ACS (NCT02484924)
- Testing
- Ticagrelor
- Where
- United Kingdom
- Volunteers
- 5,225 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
End Stage Renal Disease, Vascular Access Patency
Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
This study is a randomized, placebo-controlled, single blind clinical trial. Seventy patients with ESRD on chronic HD and a functioning AVF will be recruited.
- Trial name
- NCT02335099
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Virginia
Pharmacokinetics
KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug
The cholesterol-lowering drug rosuvastatin is a substrate of the breast cancer resistance protein (BCRP). BCRP is an efflux transporter expressed e.g. in the small intestine.
- Trial name
- KF2019#1 (NCT05373277)
- Testing
- Ticagrelor, Rosuvastatin
- Where
- Finland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital